Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large b-cell lymphomas

Genes Chromosomes and Cancer

Volumn 50, Issue 9, 2011, Pages 715-725

  Guney, Suzan ^a,b   Bertrand, Philippe ^a,b   Jardin, Fabrice ^a,b   Ruminy, Philippe ^a,b   Pierre Kerckaert, Jean ^c   Tilly, Hervé ^a,b   Bastard, Christian ^a,b  

^a Institut Fédératif de Recherches Multidisciplinaires sur les Peptides 23   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c Institut de Recherche sur le Cancer de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EXON; FEMALE; GENE CLUSTER; GENE DELETION; GENE EXPRESSION; GENE LOSS; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; HUMAN; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 79960161205     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20893     Document Type: Article

References (53)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr., Lu L, Lewis D B, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
2. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL. 1997. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57: 832-836.
3. Bertrand P, Courel MN, Maingonnat C, Jardin F, Tilly H, Bastard C. 2005. Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: Relationship with tumor aggressiveness. Int J Cancer 113: 207-212.
4. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, Ruminy P, Picquenot JM, Tilly H. 2007. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 21: 515-523.
5. Cayuela JM, Hebert J, Sigaux F. 1995. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood 85: 854.
6. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. 1996. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 87: 2180-2186.
7. Cayuela JM, Gardie B, Sigaux F. 1997. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 90: 3720-3726.
8. Cuomo CA, Mundy CL, Oettinger MA. 1996. DNA sequence and structure requirements for cleavage of V(D)J recombination signal sequences. Mol Cell Biol 16: 5683-5690.
9. Drexler HG. 1998. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12: 845-859.
10. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI. 1995. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86: 1931-1938.
11. Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI. 1998. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer 22: 72-78.
12. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. 1998. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91: 4677-4685.
13. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG. 2000. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133.
14. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87.
15. Florl AR, Schulz WA. 2003. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer 37: 141-148.
16. Gardie B, Cayuela JM, Martini S, Sigaux F. 1998. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 91: 1016-1020.
17. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP. 1995. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 86: 1534-1539.
18. Gronbaek K, de Nully BP, Moller MB, Nedergaard T, Ralfkiaer E, Moller P, Zeuthen J, Guldberg P. 2000. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 14: 1727-1735.
19. Hannon GJ, Beach D. 1994. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-261.
20. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282.
21. Hebert J, Cayuela JM, Berkeley J, Sigaux F. 1994. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84: 4038-4044.
22. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
23. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996a. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
25. Herman JG, Jen J, Merlo A, Baylin SB. 1996b. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727.
26. Jardin F, Ruminy P, Kerckaert JP, Parmentier F, Picquenot JM, Quief S, Villenet C, Buchonnet G, Tosi M, Frebourg T, Bastard C, Tilly H. 2008. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 93: 543-550.
27. Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de R A, Coiffier B, Haioun C, Leroy K. 2010. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: A GELA study. Blood 116: 1092-1104.
28. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RSIII, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
29. Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, Lieber MR, Mizoguchi H, Yokota J, Kohno T. 2002. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem 277: 46289-46297.
30. Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD. 1995. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 86: 2900-2905.
31. Kohno T, Yamada Y, Tawara M, Takasaki Y, Kamihira S, Tomonaga M, Matsuyama T. 2007. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk Res 31: 1625-1632.
32. Lee JT, Innes DJ Jr., Williams ME. 1989. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J Clin Invest 84: 1454-1459.
33. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. 2008. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105: 13520-13525.
34. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. 1993. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82: 2289-2295.
35. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J. 1997. Hypermethylation of a 5' CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 11: 425-428.
36. Matolcsy A, Casali P, Warnke RA, Knowles DM. 1996. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88: 3937-3944.
37. Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, Boutard P, Mechinaud F, Plouvier E, Otten J, Vilmer E, Cave H. 2006. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 91: 881-885.
38. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
39. Ohta S, Uemura H, Matsui Y, Ishiguro H, Fujinami K, Kondo K, Miyamoto H, Yazawa T, Danenberg K, Danenberg PV, Tohnai I, Kubota Y. 2009. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107: 81-91.
40. Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, Lee SS, Kim WH, Kim CW. 2005. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. Histopathology 47: 281-291.
41. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A, Campo E. 1998. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91: 2977-2984.
42. Ramsden DA, Gellert M. 1995. Formation and resolution of double-strand break intermediates in V(D)J rearrangement. Genes Dev 9: 2409-2420.
43. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M. 1993. p53 mutation is associated with progression in follicular lymphomas. Blood 82: 1994-2004.
44. Sato M, Sasaki H, Kazui T, Yokota J, Kohno T. 2005. Probing the chromosome 9p21 region susceptible to DNA double-strand breaks in human cells in vivo by restriction enzyme transfer. Oncogene 24: 6108-6118.
45. Senff NJ, Zoutman WH, Vermeer MH, Assaf C, Berti E, Cerroni L, Espinet B, de Misa Cabrera RF, Geerts ML, Kempf W, Mitchell TJ, Paulli M, Petrella T, Pimpinelli N, Santucci M, Whittaker SJ, Willemze R, Tensen CP. 2009. Fine-mapping chromosomal loss at 9p21: Correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 129: 1149-1155.
46. Shank-Calvo JA, Draheim K, Bhasin M, Kelliher MA. 2006. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene 25: 3023-3031.
47. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A. 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988-2994.
48. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De LC, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E. 1995. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85: 893-901.
49. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman J, editors. 2008. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
50. Taniguchi T, Chikatsu N, Takahashi S, Fujita A, Uchimaru K, Asano S, Fujita T, Motokura T. 1999. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 13: 1760-1769.
51. Timsit Y, Vilbois E, Moras D. 1991. Base-pairing shift in the major groove of (CA)n tracts by B-DNA crystal structures. Nature 354: 167-170.
52. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. 2008. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135: 1130-1142.
53. Villuendas R, Sanchez-Beato M, Martinez JC, Saez AI, Martinez-Delgado B, Garcia JF, Mateo MS, Sanchez-Verde L, Benitez J, Martinez P, Piris MA. 1998. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 153: 887-897.